GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2007

SynCo to Help Prosensa Advance its RNA-based Therapeutics for DMD

  • SynCo Bio Partners and Prosensa will collaborate in the formulation and fill of Prosensa’s RNA-based therapeutics for Duchenne muscular dystrophy (DMD).

    "SynCo is pleased to be working with Prosensa on this important clinical program for the life-saving treatment of DMD,” Pierre Warffemius, CEO of SynCo commented. “We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders by providing high quality aseptic formulation and filling services."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »